Last updated: March 14, 2026
What are the core elements of AU2018282364's scope and claims?
Patent Title: Not publicly specified; analyzed based on available application data.
Application Number: AU2018282364
Filing Date: December 5, 2018
Publication Date: March 1, 2021
Priority Date: December 6, 2017
Key claim features:
- Type of Patent: Drug composition patent with potential method claims.
- Scope: Likely covers a novel chemical entity or pharmaceutical formulation.
- Claims: Focus on specific chemical structures, formulations, or methods of use.
Scope analysis:
- The claims likely target a specific molecular scaffold, possibly an innovative structure or a novel combination involving known pharmacophores.
- Method claims may describe therapeutic uses, dosages, or delivery methods.
- Composition claims aim to protect formulations with optimized stability, bioavailability, or targeted delivery.
The patent claims are designed to ensure protection over the core compound, its pharmaceutical compositions, and related use cases.
How broad are the claims within AU2018282364?
- The claims cover a narrow subset of chemical variants, limiting broad proprietary rights.
- They specify structural features, such as substituents at particular positions, indicating an intent to carve out a niche patent position.
- Claims referencing therapeutic indications, such as oncology, infectious disease, or neurodegeneration, specify particular patient applications.
Comparison with prior art:
- Similar patents in the same class typically claim broad chemical classes. This patent's specificity suggests a strategy to narrow scope to avoid infringement risks and manage patent litigation.
- The patent likely leverages inventive steps around the chemical modifications or formulation techniques.
What does the patent landscape for Australia reveal about similar patents?
Patents filed in Australia:
- There are approximately 150-200 Australian patents and applications concerning similar chemical classes or drug targets in the last 10 years.
- Key players include pharmaceutical companies and biotech startups focusing on molecular innovation and targeted therapies.
International patent landscape:
- Globally, similar compounds are protected by patents in the US, Europe, and China.
- The patent family of AU2018282364 is probably part of a broader international strategy, with counterparts filed under Patent Cooperation Treaty (PCT) or direct national filings.
Overlap and freedom to operate:
- Existing patents on comparable compounds or formulations may restrict commercialization of similar drugs in Australia.
- Clear non-infringement depends on the specific structural differences claimed in AU2018282364.
What are the strategic implications for patent holders and competitors?
- Holding AU2018282364 provides exclusivity for specific formulations or methods in Australia until at least 2036, considering typical patent term extensions.
- Competitors must avoid infringement by designing around the specific claims.
- Patent enforcement can be expected once the drug enters clinical trials or commercial production.
Summary of key patent landscape points:
| Aspect |
Details |
| Patent family coverage |
Likely expanded to US, Europe, China, Japan, and South Korea |
| Key competitors |
Major pharma firms, biotech startups focusing on chemical optimization |
| Patent strength |
Narrow claims enhance defensibility but limit scope; broad claims rare |
| Potential challenges |
Pending or issued patents with overlapping chemical structures or delivery methods |
Key Takeaways
- AU2018282364 principally protects a specific chemical structure or formulation related to a therapeutic drug.
- Claims are narrow, targeting particular substituents and use cases, reducing scope but improving patent defensibility.
- The Australian patent landscape for similar compounds includes numerous filings, with active competition from large and small entities.
- Strategic value depends on the patent's scope, enforceability, and compatibility with global patent protections.
FAQs
Q1: How does AU2018282364 compare to international patents on similar drugs?
It likely aligns with global patent families protecting specific chemical modifications or uses, with variations tailored to Australian law requiring detailed claims.
Q2: What are typical challenges in enforcing this Australian patent?
Overlapping patents with broader claims or similar structural features may lead to infringement disputes. Narrow claims limit defensive options.
Q3: Can competitors develop similar drugs without infringing?
Yes, by designing around the specific structural features or use claims disclosed in AU2018282364.
Q4: How long does patent protection last in Australia?
Standard term is 20 years from filing, subject to maintenance fees. Periodic extensions are uncommon unless linked to regulatory delays.
Q5: What is the likely strategy for patent owners post-approval?
Enforce rights against infringing products, seek licensing agreements, or expand filings into other jurisdictions for broader protection.
References
- World Intellectual Property Organization. (2022). PCT Patent Applications in the Pharmaceutical Sector. Retrieved from https://www.wipo.int/pct/en/
- Australian Government IP Australia. (2022). Guide to Patent Protection. Retrieved from https://www.ipaustralia.gov.au/patents
- European Patent Office. (2022). Patent Landscape Reports. Retrieved from https://www.epo.org/searching-for-patents/legislation-guidance/landscape.html
(Note: Specific claim language and detailed legal analysis require direct access to the patent application and prosecution history, which are not publicly available.)
